tradingkey.logo

BRIEF-Tremfya Subcutaneous (SC) Induction Data Support Potential To Be The First To Offer The Option Of Both Intravenous And SC Induction Therapy In Ulcerative Colitis

ReutersFeb 21, 2025 12:06 PM

- Johnson & Johnson JNJ.N:

  • TREMFYA® (GUSELKUMAB) SUBCUTANEOUS (SC) INDUCTION DATA SUPPORT POTENTIAL TO BE THE FIRST AND ONLY IN ITS CLASS TO OFFER THE OPTION OF BOTH INTRAVENOUS AND SC INDUCTION THERAPY IN ULCERATIVE COLITIS

  • J&J: STUDY ACHIEVES PRIMARY AND ALL SECONDARY ENDPOINTS AT WEEK 12

  • J&J: SAFETY DATA FROM ASTRO STUDY WERE CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF TREMFYA

Source text: ID:nPn7jMWf9a

Further company coverage: JNJ.N

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI